Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,030,000 shares, a decline of 14.2% from the December 15th total of 1,200,000 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading volume of 131,000 shares, the days-to-cover ratio is currently 7.9 days.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and cut their price objective for the company from $2.25 to $1.75 in a research note on Thursday, December 5th.

Institutional Trading of Nautilus Biotechnology

Several hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in shares of Nautilus Biotechnology by 19.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock worth $1,345,000 after acquiring an additional 94,908 shares in the last quarter. Wexford Capital LP raised its holdings in Nautilus Biotechnology by 9.6% during the 3rd quarter. Wexford Capital LP now owns 228,350 shares of the company’s stock valued at $651,000 after buying an additional 20,000 shares during the period. Renaissance Technologies LLC raised its holdings in Nautilus Biotechnology by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after buying an additional 14,100 shares during the period. Barclays PLC raised its holdings in Nautilus Biotechnology by 79.6% during the 3rd quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after buying an additional 47,059 shares during the period. Finally, MetLife Investment Management LLC purchased a new stake in Nautilus Biotechnology during the 3rd quarter valued at $87,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

Nautilus Biotechnology Stock Up 1.6 %

NAUT stock traded up $0.03 during midday trading on Friday, hitting $1.93. The company’s stock had a trading volume of 77,540 shares, compared to its average volume of 149,773. Nautilus Biotechnology has a 12 month low of $1.61 and a 12 month high of $3.12. The firm has a market capitalization of $242.34 million, a price-to-earnings ratio of -3.45 and a beta of 1.20. The company has a 50 day moving average of $2.02 and a two-hundred day moving average of $2.42.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same period in the previous year, the firm earned ($0.13) EPS. On average, analysts anticipate that Nautilus Biotechnology will post -0.57 earnings per share for the current fiscal year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.